Subject:
- Active Substance: Ciltacaptagene autoleucel
- Name: Carvykti®
- Therapeutic area: Multiple myeloma
- Pharmaceutical company: Janssen-Cilag GmbH
Time table:
- Start: 15.02.2023
- Publication of assessment: 15.05.2023
- End of public hearing: 05.06.2023
- Final decision by G-BA: beginning of August 2023
Comparative therapy:
- No comparative therapy due to orphan drug designation